The Bottom Line: In this first published RCT of vitamin D supplementation in sarcoidosis, it was found that patients with sarcoidosis and 25OHD <50 nmol/L, vitamin D supplements did not alter average serum calcium or urine calcium, but had no benefit on surrogate markers of skeletal health and caused one case of significant hypercalcaemia.
Setting: Clinical research centre.
Participants: 27 normocalcaemic patients with sarcoidosis and 25-hydroxyvitamin D (25OHD) <50 nmol/L.
Intervention: 50 000 IU weekly cholecalciferol for 4 weeks, then 50 000 IU monthly for 11 months or placebo.
Strengths and limitations: The study had limited power to detect small differences in bone density and bone turnover markers. Few participants had 25-hydroxyvitamin levels <25 nmol/L, and therefore the findings may not apply to individuals with very low vitamin D levels.